Unbiased Analysis of Today's Healthcare Issues
For patients with serious illnesses, timeline access to efficacious medications is paramount. The European Medicines Agency (EMA) was created in part to help expedite drug approvals and insure these products are save and effective. As stated in a paper by Grünwald and Stargardt (2024): The EMA [European Medicines Agency] was founded in 1995 primarily to…
Hydery and Reddy (2024) provide a nice primer on drug formularies. Below is a quick overview. What is a formulary? A formulary is a continually updated list of medications, products, and technologies supported by current evidence-based medicine, as well as the judgment of physicians, pharmacists, and other relevant experts in the diagnosis and treatment of disease…
Using commercial claims data between 2009-2018, a paper in Health Services Research by Lalani et al (2024) finds that: Rebates are rising as a share of cost Fewer patients have $0 out-of-pocket cost Patient out-of-pocket costs growth was 2.9x as large as net drug cost growth Specifically: List prices increased 4.4%/yr (interquartile range [IQR], 1.1%…
That is the title of a recent paper by Hernandez and Hung (2024). The article provides an excellent review of how drugs get reimbursed in the US and who the key players are. I provide an abbreviated summary below, but do read the full article. The players Manufacturers research, develop, and bring new drug products…
I just came across a nice overview article titled The financial ecosystem of pharmaceutical R&D. The white paper was developed for the Netherlands government and provides an overview of the drug development process and how (and by whom) it is financed. The white paper answers the following questions: What do different players do within the…
According to the OECD, In 2021 the U.S. spent $1,432/capita on pharmaceuticals compared to only $517/per capita in the UK. The UK’s figure was slightly higher that Poland and Norway, but less than Latvia, the Slovak Republic, Portugal and Romania. How does the UK spend so little on drugs? Many people focus on the efforts…
Pham et al. (2023) uses data on regulatory decisions and health technology assessments (HTAs) in Australia, Canada, and the UK and compares them to the drugs that are FDA-approved in the US. They find that: The FDA approved 206 new drugs in 2017 through 2020, of which 162 (78.6%) were granted marketing authorization by at…
That is the title of an FTI White Paper published this year where I was a co-author alongside Antoine Mialhe, Sabiha Quddus, Anne-Sophie Deman, Suhail Thahir and Agnes Sipiczki. The role of Intellectual property (IP) in the development of COVID-19 vaccines and therapeutics became a central tenant in discussions on how to ensure access to…
Based on one study from Sweden, the answer is ‘no’. A paper by Johansson and Svensson (2022) use data from Sweden on regional variation in drug spending. First, some background on the Swedish approach for prescription drugs spending. The Swedish national health service offers universal coverage for all residents. The system is decentralized in 21…
An article from the Health Affairs forefront article from Ho and Vertinsky (2022) argues ‘yes’, but the use of any such such information for cost-based pricing is short-sighted. The Ho and Vertinsky say drug cost disclosure would be useful because (i) currently there is little information on the cost of drug development, (ii) it is…